Clinical trials can now incorporate remote activities such as telehealth visits, home-based procedures, electronic consent, direct-to-participant services, and digital data collection. However, a decentralized clinical trial (DCT) is not created simply by adding separate digital tools. The technology, workflows, data sources, and oversight processes need to work together within the study protocol and applicable regulatory requirements.
A capable decentralized clinical trials platform should therefore support participant interaction, investigator oversight, data capture, system integration, and quality controls. FDA guidance on decentralized clinical trials addresses remote visits, digital health technologies, informed consent, investigational products, and participant safety.
What Should a Decentralized Clinical Trial Platform Provide?
A DCT platform should connect the digital components required to conduct appropriate trial activities away from conventional research sites while maintaining controlled data and operational workflows.
Common capabilities include electronic informed consent, electronic clinical outcome assessments (eCOA), electronic patient-reported outcomes, telemedicine or TeleVisit functions, remote monitoring, direct-to-patient services, and digital health technologies. The appropriate combination depends on the protocol, therapeutic area, participant population, and activities being decentralized.
For sponsors considering decentralized clinical trials, the key consideration is therefore not the number of digital functions available, but whether they fit the protocol and can operate within a controlled clinical trial environment.
How Does eCOA Support Remote Data Collection?
eCOA enables participants to complete specified clinical assessments electronically instead of relying solely on paper questionnaires.
Depending on the protocol, these assessments can include patient-reported, clinician-reported, observer-reported, or performance-related outcomes. The electronic format should preserve the intended assessment while providing appropriate controls for data collection and transfer.
A DCT platform should therefore address more than the participant interface. It should also support data identification, transmission, review, and integration with the broader clinical data environment.
Why Is Telemedicine Integration Important?
Telemedicine can support remote interactions between participants and qualified clinical personnel when the protocol allows an activity to be performed outside a traditional site.
However, a virtual visit does not automatically make a study decentralized. The activity must be appropriate for remote delivery, with responsibilities for participant assessment, safety monitoring, documentation, and follow-up clearly defined.
For this reason, telemedicine integration should extend beyond video conferencing. The platform should support the workflow surrounding remote visits and connect relevant information with the wider clinical trial system.
What Role Does eConsent Play in a DCT Platform?
Electronic informed consent can allow participants to review consent information and provide consent electronically when applicable requirements are met.
Because participants may complete parts of enrollment remotely, eConsent can be particularly relevant to decentralized models. However, technology does not replace the informed consent process itself.
A suitable platform should provide controls for participant identity, consent documentation, version management, and record retention. The workflow should also reflect the responsibilities of investigators and other authorized personnel while meeting applicable requirements for electronic records, signatures, and IRB oversight.
How Does Tigermed’s DCT Platform Approach These Functions?
Tigermed combines digital tools with clinical trial services rather than treating decentralization as a single software function.
Its published DCT portfolio includes eCOA, TeleVisit, eConsent, ePRO/eDiary, direct-to-patient services, electronic payment, digital health technologies, remote study visits, and risk-based or remote monitoring. The platform also includes integration-oriented functions designed to connect different sources of trial information.
Tigermed reports that more than 300 clinical trials have incorporated DCT elements and that more than 40% of its ongoing clinical trials incorporate DCT elements. These figures are company-reported and should be considered within the company’s stated reporting scope and period.
How Should Remote Monitoring Be Built Into the Technology Model?
Remote monitoring allows appropriate trial information to be reviewed without requiring every monitoring activity to occur on site. The monitoring approach should be determined according to study risks and operational characteristics.
The draft ICH E6(R3) Annex 2 emphasizes proportionate, risk-based approaches to clinical trial quality when decentralized methodologies and multiple data sources are used.
Tigermed’s DCT platform includes CTRM and risk-based quality management capabilities, while its broader clinical monitoring services include remote and risk-based monitoring. This allows monitoring technology to be considered as part of the overall quality management process.
How Can Sponsors Validate DCT Technology for GCP Compliance?
DCT technology should be validated according to its intended use and potential impact on participant safety, data integrity, and study reliability.
Validation should go beyond checking whether an application performs basic functions. Sponsors should establish system requirements, testing procedures, access controls, data flows, audit trails, change management, backup arrangements, and training according to the system’s intended use and risk.
FDA guidance on electronic systems recommends a risk-based validation approach that considers potential effects on safety, quality, and record integrity. Electronic records should also support reconstruction of the trial, while audit trails should capture relevant changes to electronic records.
Validation should therefore take place before deployment and be revisited when significant system changes occur.
What Should Sponsors Evaluate in a DCT Platform?
A practical assessment should focus on four areas: functionality, integration, compliance, and operational fit.
Functionality determines whether the platform can support the required remote activities. Integration examines how data move between participant-facing tools, clinical systems, and other sources. Compliance covers validation, electronic records, audit trails, access controls, privacy, and applicable regulatory requirements. Operational fit considers whether participants, investigators, sites, and study teams can use the technology effectively within the actual protocol.
A DCT platform ultimately functions as part of the clinical trial infrastructure. eCOA, telemedicine, eConsent, remote monitoring, and other digital components address different operational needs, but their value depends on integration and governance. Sponsors evaluating a DCT solution should therefore assess the complete workflow rather than simply comparing the number of digital features.
